Kyverna Therapeutics, Inc. (KYTX)
↓ Download CSVKey ratios (FY2025)
-69.4%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating Income | -$169.83M | -$142.60M | -$62.41M | — |
| Net Income | -$161.31M | -$127.48M | -$60.37M | — |
| EPS (Diluted) | $-3.64 | $-3.33 | $-89.61 | — |
| Total Assets | $293.83M | $304.64M | $75.19M | — |
| Total Liabilities | $61.55M | $38.06M | $26.02M | — |
| Shareholders' Equity | $232.28M | $266.59M | -$13.14M | -$74.00M |
| Cash & Equivalents | $124.09M | $96.62M | $34.65M | — |
| Operating Cash Flow | -$153.71M | -$114.25M | -$52.41M | — |
| Capital Expenditures | $5.0K | $2.21M | $621.0K | — |
| Shares Outstanding | 60.39M | 43.21M | 1.25M | — |